Bellicum reports clinical hold placed on bpx-601 phase 1/2 clinical trial

Houston, dec. 07, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the u.s. food and drug administration (fda) that a clinical hold has been placed on patient enrollment and dosing in an ongoing phase 1/2 dose-escalation clinical trial evaluating bpx-601 in patients with previously treated metastatic pancreatic or prostate cancer. the fda is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. the clinical investigator and bellicum classified the patient death as unrelated to bpx-601 and rimiducid.
BLCM Ratings Summary
BLCM Quant Ranking